Efficacy evaluation of multi-immunotherapy in ovarian cancer: from bench to bed
X Hu, C Bian, X Zhao, T Yi - Frontiers in immunology, 2022 - frontiersin.org
Ovarian cancer, one of the most common gynecological malignancies, is characterized by
high mortality and poor prognosis. Cytoreductive surgery and chemotherapy remain the …
high mortality and poor prognosis. Cytoreductive surgery and chemotherapy remain the …
Discovery of novel and selective SIK2 inhibitors by the application of AlphaFold structures and generative models
Abstract Salt-inducible kinase 2 (SIK2) has been recognized as a potential target for anti-
inflammation and anti-cancer therapy. In this paper, based on the binding pose of the …
inflammation and anti-cancer therapy. In this paper, based on the binding pose of the …
ROS responsive nanoparticles encapsulated with natural medicine remodel autophagy homeostasis in breast cancer
X Zhang, H Gao, D Wei, X Pei, Y Zhang… - … Applied Materials & …, 2023 - ACS Publications
In photodynamic therapy (PDT), elevated reactive oxygen species (ROS) activate tumor cell
protective autophagy, therefore attenuating the antitumor function of therapy. Hence …
protective autophagy, therefore attenuating the antitumor function of therapy. Hence …
Roles of salt‑inducible kinases in cancer
S Feng, F Wei, H Shi, S Chen… - International …, 2023 - spandidos-publications.com
Salt inducible kinases (SIKs) with three subtypes SIK1, SIK2 and SIK3, belong to the AMP‑
activated protein kinase family. They are expressed ubiquitously in humans. Under normal …
activated protein kinase family. They are expressed ubiquitously in humans. Under normal …
Optimization of selectivity and pharmacokinetic properties of salt-inducible kinase inhibitors that led to the discovery of pan-SIK inhibitor GLPG3312
T Temal-Laib, C Peixoto, N Desroy… - Journal of Medicinal …, 2023 - ACS Publications
Salt-inducible kinases (SIKs) SIK1, SIK2, and SIK3 are serine/threonine kinases and form a
subfamily of the protein kinase AMP-activated protein kinase (AMPK) family. Inhibition of …
subfamily of the protein kinase AMP-activated protein kinase (AMPK) family. Inhibition of …
Extracellular vesicle-packaged circBIRC6 from cancer-associated fibroblasts induce platinum resistance via SUMOylation modulation in pancreatic cancer
S Zheng, Q Tian, Y Yuan, S Sun, T Li, R Xia… - Journal of Experimental …, 2023 - Springer
Abstract Background Cancer-associated fibroblasts (CAFs) play pivotal roles in
chemoresistance of pancreatic ductal adenocarcinoma (PDAC). However, the underlying …
chemoresistance of pancreatic ductal adenocarcinoma (PDAC). However, the underlying …
Discovery of Clinical Candidate GLPG3970: A Potent and Selective Dual SIK2/SIK3 Inhibitor for the Treatment of Autoimmune and Inflammatory Diseases
C Peixoto, A Joncour, T Temal-Laib… - Journal of Medicinal …, 2024 - ACS Publications
The salt-inducible kinases (SIKs) SIK1, SIK2, and SIK3 belong to the adenosine
monophosphate-activated protein kinase (AMPK) family of serine/threonine kinases. SIK …
monophosphate-activated protein kinase (AMPK) family of serine/threonine kinases. SIK …
Discovering breast cancer biomarkers candidates through mRNA expression analysis based on the cancer genome atlas database
DH Kim, KE Lee - Journal of Personalized Medicine, 2022 - mdpi.com
Background: Research on the discovery of tumor biomarkers based on big data analysis is
actively being conducted. This study aimed to secure foundational data for identifying new …
actively being conducted. This study aimed to secure foundational data for identifying new …
[HTML][HTML] Synergistic antitumor efficacy of rMV-Hu191 and Olaparib in pancreatic cancer by generating oxidative DNA damage and ROS-dependent apoptosis
L Jiang, X Zhou, Y He, Y Liu, D Zhou, Y Lv, B Wu… - Translational …, 2024 - Elsevier
Background Malignancies with BRCA1/2 deficiencies are particularly sensitive to PARP
inhibitors. Thus, combining PARP inhibitors with agents that impair DNA damage repair to …
inhibitors. Thus, combining PARP inhibitors with agents that impair DNA damage repair to …
[HTML][HTML] A novel SIK2 inhibitor SIC-19 exhibits synthetic lethality with PARP inhibitors in ovarian cancer
F Wang, X Yu, J Qian, Y Cao, S Dong, S Zhan… - Drug Resistance …, 2024 - Elsevier
Purpose Ovarian cancer patients with HR proficiency (HRP) have had limited benefits from
PARP inhibitor treatment, highlighting the need for improved therapeutic strategies. In this …
PARP inhibitor treatment, highlighting the need for improved therapeutic strategies. In this …